2020. An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s27. DOI:https://doi.org/10.25251/skin.4.supp.27.